mAbs

Views & Analysis

Artificial Intelligence for better antibody drugs: ready for...

The potential of monoclonal antibodies (mAbs) as therapies is indisputable. The current mAbs market is expected to be around ~USD 150 billion.

Views & Analysis

How-cell-and-gene-therapies-are-transforming-the-pace-of-deal-making

How cell and gene therapies are transforming pharma deal-mak...

After decades of clinical research targeting development of more “personalised” medicines, the biotechnology sector is now starting to deliver with the first generation of promising new cel

News

NHS "isn't delivering equitable care for rare diseases"

A Genetic Alliance UK report claims the NHS is failing to meet the needs of many of the 3.5 million people in the country who live with rare diseases.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/register.png

Sales & Marketing

Using AI-driven synthetic personas to take your insights fur...

As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.

Editor's Picks